Pharmidex Announcement: Dr. Christopher Ireson’s New Role
January 28, 2025
We are excited and proud to share that our Head of Oncology, Dr. Christopher Ireson, has been named as a member of the Translational Advisory Board of the Brain Tumour Charity! 🧠💼
Dr. Ireson’s extensive expertise in oncology will help drive impactful scientific advancements and translational research to improve outcomes for brain tumour patients. We are incredibly grateful to have such a talented leader in our team contributing to this important cause. 🌟
Please join us in congratulating Dr. Ireson on this achievement! 👏
#Pharmidex #Oncology #TranslationalResearch #BrainTumourCharity #ProudMoment #ScientificAdvisoryBoard
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. 👩🔬 👨🔬 Welcome to the team, Gabrielle and Mohammed!
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: ✅ Bitter-tasting APIs ✅ Unpalatable excipients ✅ The success of taste-masking strategies ✅ Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs. ✅ Human-relevant metabolism data ✅ Supports IND-enabling ®gulatory studies ✅ Ideal for metabolite profiling, DDI risk & toxicity assessment By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development. 📩 Contact us to see how 8HUM can support your project.
